Infection
Conditions
Interventions
MIPD group:Vancomycin regimen are determined by clinical physicians (or in discussion with clinical pharmacists) based on MIPD advices and patient conditions.
Control group:Vancomycin regimen are determined by clinical physicians (or in discussion with clinical pharmacists) based on TDM results and patient conditions.
Sponsors
Nanjing Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.Patients who received intravenous Vancomycin Hydrochloride during hospitalization and received therapeutic drug monitoring at least once during the treatment period. 2.Aged =18 years.
Exclusion criteria
Exclusion criteria: 1.Patients undergoing renal replacement therapy during vancomycin treatment, or those with a history of acute or chronic kidney disease or kidney transplant before vancomycin treatment. 2.Pregnant women, burn victims, and patients with cystic fibrosis (a group excluded from MIPD modeling due to altered pharmacokinetics). 3.Patients concurrently receiving vancomycin through non-intravenous routes (such as intra-articular or intraventricular administration). 4.Patients who received vancomycin for less than 72 hours. 5.Patients with incomplete clinical data and medication history.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical cura rate;Acute kidney injury;Direct medical cost; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vancomycin concentration;Bacteria culture test; | — |
Countries
China
Contacts
Public ContactZhu Huaijun
Nanjing Drum Tower Hospital
Outcome results
None listed